- Home
- PHIO
as 07-08-2024 4:00pm EST
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 2.7M | IPO Year: | N/A |
| Target Price: | $4.00 | AVG Volume (30 days): | 8.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -29.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.50 - $29.07 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Phio Pharmaceuticals Corp. (PHIO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bitterman Robert J | PHIO | President & CEO | Jun 7 '24 | Buy | $0.74 | 1,000 | $740.00 | 20,990 | SEC Form 4 |
| Bitterman Robert J | PHIO | President & CEO | Jun 6 '24 | Buy | $0.75 | 1,000 | $750.00 | 19,990 | SEC Form 4 |
| Bitterman Robert J | PHIO | President & CEO | Feb 26 '24 | Buy | $0.91 | 2,500 | $2,275.00 | 18,990 | SEC Form 4 |
Latest Phio Pharmaceuticals Corp. News
PHIO Breaking Stock News: Dive into PHIO Ticker-Specific Updates for Smart Investing
Newsfile
12 hours ago
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
Newsfile
3 days ago
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
MT Newswires
6 days ago
Phio Pharmaceuticals Board Approves 1-For-9 Reverse Stock Split
Newsfile
6 days ago
Phio Pharmaceuticals Announces Reverse Stock Split
Newsfile
21 days ago
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
Newsfile
a month ago
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
Newsfile
2 months ago
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
MT Newswires
2 months ago
Phio Pharmaceuticals Files $100 Million Mixed Shelf
Share on Social Networks:
Disclaimer
The information presented on this page, "PHIO Phio Pharmaceuticals Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.